Horizon Therapeutics Shares Jump On Confirmation Of Takeover Talks With Several Large Companies
Horizon Therapeutics Plc (NASDAQ:HZNP) confirmed it’s engaged in preliminary talks with Amgen Inc (NASDAQ: AMGN), Janssen Global Service, and Sanofi SA (NASDAQ: SNY) on potential takeover offers for…
Drugs for Neglected Diseases Initiative and Sanofi Announced Treatment Success Rates of Up to 95% From a Phase II/II Study Investigating the Safety and Efficacy of Single-dose Acoziborole for Sleeping Sickness
The Drugs for Neglected Diseases initiative (DNDi) and Sanofi announce treatment success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole, a potentially transformative investigational treatment for sleeping sickness, published today in The Lancet Infectious Diseases medical journal.
UK’s Medicines And Healthcare Products Regulatory Agency Says Professionals Prescribing Dupilumab Should Be Alert To Risks Of Ocular Reactions, New Or Worsening Ocular Symptoms Require Prompt Review
https://www.gov.uk/drug-safety-update/dupilumab-dupixentv-risk-of-ocular-adverse-reactions-and-need-for-prompt-management
First Drug That Can Delay Onset of Type 1 Diabetes Gets FDA Approval After Multiple Regulatory Hurdles
The FDA approved Provention Bio Inc’s (NASDAQ:PRVB) Tzield (teplizumab-mzwv) injection to delay the onset of stage 3 type 1 diabetes in…
Europe Approves Sanofi, GSK’s Beta Variant Adapted COVID Shot As Booster
The European Commission has approved Sanofi SA (NASDAQ: SNY) and GSK plc (NYSE:GSK) partnered COVID-19 vaccine booster after the European Medicines Agency’s Committee for…
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
The European Commission has approved AstraZeneca plc (NASDAQ:AZN) and Sanofi SA’s (NASDAQ:SNY) Beyfortus (nirsevimab) long-acting antibody to prevent respiratory syncytial virus (RSV) lower…
Sanofi: Q3 Earnings Insights
Sanofi (NASDAQ:SNY) reported its Q3 earnings results on Friday, October 28, 2022 at 05:00 AM.
Here's what investors need to know about the announcement.
Earnings
Sanofi beat estimated earnings by 9.02%, reporting an EPS of $1.45 versus an estimate of $1.33.